SCHEMBL19797207

SCHEMBL19797207

c1ccc(N(c2ccc3c(c2)C(c2ccccc2)(c2ccccc2)c2ccccc2-3)c2ccc3c(c2)C2(c4ccccc4-c4ccccc42)c2cc4ccccc4cc2-3)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PDK2 Q15119 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ ESR1 P03372 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19822141 1.00 KDM4E (0.41) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL24466810 0.97 MEN1 (0.42) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL24466743 0.96 MEN1 (0.45) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL24476719 0.96 MEN1 (0.44) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL24466752 0.95 KDM4E (0.40) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL23597916 0.95 KDM4E (0.39) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL23597988 0.95 KDM4E (0.39) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL24371889 0.94 KDM4E (0.38) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL19797209 0.94 PDK2 (0.42) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL19822155 0.94 PDK2 (0.42) KDM4EMAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11711973-B2 Organic electronic device DUK SAN NEOLUX CO., LTD. (KR) 2023-07-25 — — US disclosed
US-20230111469-A1 Organic Electronic Device DUK SAN NEOLUX CO., LTD. (KR) 2023-04-13 — — US disclosed
US-10283716-B2 Compound for organic electric element, organic electric element using the same, and electronic device comprising same DUK SAN NEOLUX CO., LTD. (KR) 2019-05-07 — — US disclosed
WO-2018034517-A1 COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME, AND ELECTRONIC DEVICE THEREFOR 덕산네오룩스 주식회사 2018-02-22 — — WO disclosed
WO-2018026197-A1 COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC APPARATUS COMPRISING SAME 덕산네오룩스 주식회사 2018-02-08 — — WO disclosed
US-20180026187-A1 NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME DUK SAN NEOLUX CO., LTD. (KR) 2018-01-25 — — US disclosed
US-20180026187-A1 NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME DUK SAN NEOLUX CO., LTD. (KR) 2018-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180026187-A1 NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME EBPL, OR51E2, EML4 KDM4E 1089/4885MAPT 1971/4885MEN1 1483/4885
US-10283716-B2 Compound for organic electric element, organic electric element using the same, and electronic device comprising same EBPL, OR51E2, EML4 KDM4E 956/4885MAPT 1604/4885MEN1 1376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback